The Effect of Continuous, Various Doses of Furosemide Drip on Hearing as Measured by Acoustic Emission
NCT ID: NCT00945386
Last Updated: 2009-07-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
60 participants
OBSERVATIONAL
2009-08-31
2010-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This study will monitor hearing status of these children prior to their therapy with furosemide, during this therapy and after.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Efficacy of Nasal Steroids in Treatment of Otitis Media With Effusion: Acomparative Study
NCT03491098
The Effect of Patient's Position After Intra-tympanic Injection on the Amount of Fluid in the Middle Ear
NCT04449848
The Effect of Patient's Position After Intra-tympanic Injection
NCT04384640
Otoprotection With SPI-1005 for Prevention of Temporary Auditory Threshold Shift
NCT01444846
High Dose Oral Steroids in Sudden Sensorineural Hearing Loss
NCT03255473
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Acoustic emission test will be done prior to therapy and q48 hours during their course of treatment with furosemide drip.
Dosage of furosemide drip, boluses and other relevant medications (i.e - vancomycin, muscular relaxants, aminoglycosides etc) will be recorded.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
1 Month
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Rabin Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Rabin Medical Center
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Elhanan Nahum, MD
Role: STUDY_DIRECTOR
Schneider Children's Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pediatric ICU, Schneider Children's Hospital
Petah Tikva, , Israel
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Miriam Davidowitz, MD
Role: CONTACT
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
005418
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.